INS and Glucose intolerance: Immunosuppressive therapy has been shown to be associated with glucose intolerance and post-transplantation diabetes mellitus; such a diabetogenic effect is common to immune-modulating agents acting via different mechanisms of action3,9,55, including β cell failure4,13,56,57 and alteration of metabolic parameters controlled by insulin signaling58–61.